Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 52 1 Trial showed reduction in annual cumulative steroid dose vs placebo ...

Novartis said that its immunology drug Cosentyx met the primary target and all secondary ones in a late-stage trial for the treatment of patients with inflammatory disease polymyalgia rheumatica.

Basel, October 22, 2025 – Novartis today announced that Cosentyx® (secukinumab) met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial 1. Cosentyx demonstrated ...

Data highlight potential of Cosentyx as novel targeted PMR treatment, second most common inflammatory disease in adults ≥502, with limited options available Basel, October 22, 2025 - Novartis today ...

Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying patients prescribed Cosentyx (secukinumab) the ...

Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November. The drug’s manufacturer, Novartis, said Sept.

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

Novartis (NYSE:NVS) (OTCPK:NVSEF) announced Thursday that its FDA-approved anti-inflammatory agent Cosentyx failed to reach the main goal in a Phase 3 trial for adults with giant cell arteritis ((GCA) ...

ZURICH, July 3 (Reuters) - Novartis (NOVN.S), opens new tab said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), a condition ...

The internet is good for plenty of things, but perhaps its most underrated value is its ability to turn an absolute nothingburger of a question into a worldwide search for truth. Case in point: the ...

Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as the ...